Wang Dan, Ren Yu-Meng, Guo Yi-Xuan, Zhang Zhi-Qi, Sui He-, Zhang Hai-Yan
College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Front Pharmacol. 2024 Jul 24;15:1425094. doi: 10.3389/fphar.2024.1425094. eCollection 2024.
Depression manifests as a mental disorder characterized by a low mood, suicidal tendencies, disturbances in sleep-wake cycles, psychomotor agitation, and pronounced feelings of hopelessness and anhedonia. Baicalin, a natural flavonoid compound, shows significant promise in alleviating depressive symptoms in animals. This study aims to assess the impact of baicalin on experimental models of depression.
A systematic search of electronic databases was conducted using the search terms "baicalin" AND "depression" OR "depressed" OR "anti-depression". Preclinical animal models representing experimental depression were included in the analysis. The risk of bias in the included studies was evaluated using the CAMARADES tools.
Baicalin significantly increased sucrose preference test (SPT) [SMD= 21.31, 95%CI (16.32, 26.31), < 0.00001]. mThe tail suspension test (TST) duration significantly decreased in the baicalin group compared to the model group [SMD = -39.3, 95%CI (-49.71, -28.89), < 0.0001]. Furthermore, baicalin reduced immobility time in rats subjected to the forced swim test (FST) [SMD = -39.73, 95%CI (-48.77, -30.69) < 0.0001]. Compared to the model group, baicalin treatment also significantly increased the frequency of crossings in the open field test (OFT) [SMD = 32.44, 95%CI (17.74, 47.13), < 0.00001].
Baicalin significantly improves the manifestations of depressive symptoms. The effect of baicalin against depression is exerted through its anti-inflammatory actions, inhibition of oxidative stress, regulation of the HPA axis, and restoration of neuroplasticity. Future studies will be needed to further explore how these promising preclinical findings can be translated into clinical treatment for depression.
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023472181.
抑郁症表现为一种精神障碍，其特征为情绪低落、有自杀倾向、睡眠-觉醒周期紊乱、精神运动性激越，以及明显的绝望感和快感缺失。黄芩苷是一种天然黄酮类化合物，在减轻动物抑郁症状方面显示出显著前景。本研究旨在评估黄芩苷对抑郁症实验模型的影响。
使用搜索词“黄芩苷”和“抑郁症”或“抑郁”或“抗抑郁”对电子数据库进行系统检索。分析纳入代表实验性抑郁症的临床前动物模型。使用CAMARADES工具评估纳入研究的偏倚风险。
黄芩苷显著提高了蔗糖偏好试验（SPT）[标准化均数差（SMD）=21.31，95%置信区间（CI）（16.32，26.31），P<0.00001]。与模型组相比，黄芩苷组的悬尾试验（TST）持续时间显著缩短[SMD = -39.3，95%CI（-49.71，-28.89），P<0.0001]。此外，黄芩苷减少了强迫游泳试验（FST）大鼠的不动时间[SMD = -39.73，95%CI（-48.77，-30.69），P<0.0001]。与模型组相比，黄芩苷治疗还显著增加了旷场试验（OFT）中的穿越频率[SMD = 32.44，95%CI（17.74，47.13），P<0.00001]。
黄芩苷显著改善抑郁症状的表现。黄芩苷抗抑郁作用是通过其抗炎作用、抑制氧化应激、调节下丘脑-垂体-肾上腺（HPA）轴以及恢复神经可塑性来实现的。未来需要进一步研究，以探索这些有前景的临床前研究结果如何转化为抑郁症的临床治疗方法。
